Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lidocaine - Orexa

Next Previous
X
Search
Drug Profile

Lidocaine - Orexa

Alternative Names: ORE-001

Latest Information Update: 12 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orexa
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cell membrane permeability inhibitors; Opioid receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Postoperative ileus

Most Recent Events

  • 11 Jan 2024 Phase-II clinical trials in Postoperative ileus (Prevention) in Germany (PO) (NCT05923086) (EudraCT 2022-503113-31-00-IN-002)
  • 11 Jul 2023 Orexa has patent protection for mechanism of action of lidocaine
  • 11 Jul 2023 Orexa plans a phase IIa trial in Cachexia & Sarcopenia (PO) in Q2 2025 (Orexa website; July 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top